This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Genentech, Inc., Hoffmann-La Roche Inc.. Active years: 2020-2025.
Company Filing History:
3 out of 3,292 
3 out of 5,016 
Years Active: 2020-2025
Title: Whitney Kirschbrown: Innovator in Cancer Treatment
Introduction
Whitney Kirschbrown is a notable inventor based in South San Francisco, CA (US). He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 3 patents, Kirschbrown has focused on developing advanced therapeutic formulations.
Latest Patents
One of his latest patents is the "Pertuzumab plus trastuzumab fixed dose combination." This invention concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (rHuPH20), which is administered subcutaneously to patients. The patent also discloses the final efficacy and safety data for the FeDeriCa clinical trial, along with the United States Prescribing Information (USPI) and primary analysis of the PHranceSCa clinical trial. Another significant patent is for "Subcutaneous HER2 antibody formulations." This patent provides fixed dose HER2 antibody formulations for subcutaneous administration, including fixed dose subcutaneous formulations of pertuzumab and co-formulations of pertuzumab and trastuzumab for cancer treatment.
Career Highlights
Throughout his career, Kirschbrown has worked with prominent companies such as Genentech, Inc. and Hoffmann-La Roche Inc. His work has been instrumental in advancing cancer therapies and improving patient outcomes.
Collaborations
Kirschbrown has collaborated with talented professionals in the field, including Sarah Heeson and Tanja Badovinac-Crnjevic. These collaborations have contributed to the success of his innovative projects.
Conclusion
Whitney Kirschbrown is a distinguished inventor whose work in cancer treatment has led to significant advancements in therapeutic formulations. His patents reflect a commitment to improving patient care and outcomes in oncology.